lemborexant治疗合并症失眠的安全性和实际疗效

Q1 Medicine
Narimasa Katsuta, Keitaro Takahashi, Yui Kurosawa, Akane Yoshikawa, Yoshihide Takeshita, Yoshihiro Uchida, Seita Yasuda, Chihiro Kakiuchi, Masanobu Ito, Tadafumi Kato
{"title":"lemborexant治疗合并症失眠的安全性和实际疗效","authors":"Narimasa Katsuta,&nbsp;Keitaro Takahashi,&nbsp;Yui Kurosawa,&nbsp;Akane Yoshikawa,&nbsp;Yoshihide Takeshita,&nbsp;Yoshihiro Uchida,&nbsp;Seita Yasuda,&nbsp;Chihiro Kakiuchi,&nbsp;Masanobu Ito,&nbsp;Tadafumi Kato","doi":"10.1016/j.sleepx.2023.100070","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>To investigate the real-world effectiveness and safety of lemborexan for treating comorbid insomnia associated with other psychiatric disorders, and whether lemborexant helps reduce the dose of benzodiazepines (BZs).</p></div><div><h3>Methods</h3><p>This retrospective observational study was conducted on outpatients and inpatients treated by physicians of Juntendo University Hospital Mental Clinic between April 2020 and December 2021.</p></div><div><h3>Results</h3><p>Data of 649 patients who were treated with lemborexant were eventually enrolled. About 64.5% of patients were classified as the responder group. Response rates of ≥60% were recorded for most psychiatric disorders. Upon administration of lemborexant, diazepam-equivalent dose of BZs had been significantly reduced in participants (3.7 ± 8.2 vs. 2.9 ± 7.9, p &lt; 0.001). The results of logistic regression analysis showed that outpatient (odds ratios: 2.310; 95% confidence interval [CI]: 1.32–4.05), shorter duration of BZ use (&lt;1 year) (odds ratios: 1.512; 95% CI: 1.02–2.25), no adverse events (odds ratios: 10.369; 95% CI: 6.13–17.54), larger reduction of diazepam-equivalent dose of BZs upon introducing lemborexant prescription (odds ratios: 1.150; 95% CI: 1.04–1.27), and suvorexant was the replacement drug (odds ratios: 2.983; 95% CI: 1.44–6.19), which were significant predictors of good response.</p></div><div><h3>Conclusion</h3><p>Although this is a retrospective and observational study with many limitations, our study results suggest that lemborexant is effective and safe.</p></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"5 ","pages":"Article 100070"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091115/pdf/main.pdf","citationCount":"0","resultStr":"{\"title\":\"Safety and real-world efficacy of lemborexant in the treatment of comorbid insomnia\",\"authors\":\"Narimasa Katsuta,&nbsp;Keitaro Takahashi,&nbsp;Yui Kurosawa,&nbsp;Akane Yoshikawa,&nbsp;Yoshihide Takeshita,&nbsp;Yoshihiro Uchida,&nbsp;Seita Yasuda,&nbsp;Chihiro Kakiuchi,&nbsp;Masanobu Ito,&nbsp;Tadafumi Kato\",\"doi\":\"10.1016/j.sleepx.2023.100070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim</h3><p>To investigate the real-world effectiveness and safety of lemborexan for treating comorbid insomnia associated with other psychiatric disorders, and whether lemborexant helps reduce the dose of benzodiazepines (BZs).</p></div><div><h3>Methods</h3><p>This retrospective observational study was conducted on outpatients and inpatients treated by physicians of Juntendo University Hospital Mental Clinic between April 2020 and December 2021.</p></div><div><h3>Results</h3><p>Data of 649 patients who were treated with lemborexant were eventually enrolled. About 64.5% of patients were classified as the responder group. Response rates of ≥60% were recorded for most psychiatric disorders. Upon administration of lemborexant, diazepam-equivalent dose of BZs had been significantly reduced in participants (3.7 ± 8.2 vs. 2.9 ± 7.9, p &lt; 0.001). The results of logistic regression analysis showed that outpatient (odds ratios: 2.310; 95% confidence interval [CI]: 1.32–4.05), shorter duration of BZ use (&lt;1 year) (odds ratios: 1.512; 95% CI: 1.02–2.25), no adverse events (odds ratios: 10.369; 95% CI: 6.13–17.54), larger reduction of diazepam-equivalent dose of BZs upon introducing lemborexant prescription (odds ratios: 1.150; 95% CI: 1.04–1.27), and suvorexant was the replacement drug (odds ratios: 2.983; 95% CI: 1.44–6.19), which were significant predictors of good response.</p></div><div><h3>Conclusion</h3><p>Although this is a retrospective and observational study with many limitations, our study results suggest that lemborexant is effective and safe.</p></div>\",\"PeriodicalId\":37065,\"journal\":{\"name\":\"Sleep Medicine: X\",\"volume\":\"5 \",\"pages\":\"Article 100070\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091115/pdf/main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep Medicine: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590142723000101\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep Medicine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590142723000101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的研究乐莫沙治疗与其他精神疾病相关的共病性失眠的真实有效性和安全性,方法对2020年4月至2021年12月期间由Juntendo大学医院精神诊所医生治疗的门诊和住院患者进行回顾性观察研究。约64.5%的患者被归类为应答组。大多数精神疾病的有效率≥60%。在给药lemborexant后,参与者中BZs的地西泮等效剂量显著降低(3.7±8.2 vs.2.9±7.9,p<;0.001)。逻辑回归分析结果显示,门诊患者(比值比:2.310;95%置信区间[CI]:1.32–4.05)、,无不良事件(比值比:10.369;95%可信区间:6.13-17.54),在引入lemborexant处方后,BZs的地西泮等效剂量减少幅度更大(比值比为:1.150;95%置信区间:1.04-1.27),suvorexant为替代药物(比值比2.983;95%可信范围:1.44-6.19),这些都是良好反应的重要预测因素。结论尽管这是一项具有许多局限性的回顾性和观察性研究,但我们的研究结果表明,雷博瑞吨是有效和安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety and real-world efficacy of lemborexant in the treatment of comorbid insomnia

Aim

To investigate the real-world effectiveness and safety of lemborexan for treating comorbid insomnia associated with other psychiatric disorders, and whether lemborexant helps reduce the dose of benzodiazepines (BZs).

Methods

This retrospective observational study was conducted on outpatients and inpatients treated by physicians of Juntendo University Hospital Mental Clinic between April 2020 and December 2021.

Results

Data of 649 patients who were treated with lemborexant were eventually enrolled. About 64.5% of patients were classified as the responder group. Response rates of ≥60% were recorded for most psychiatric disorders. Upon administration of lemborexant, diazepam-equivalent dose of BZs had been significantly reduced in participants (3.7 ± 8.2 vs. 2.9 ± 7.9, p < 0.001). The results of logistic regression analysis showed that outpatient (odds ratios: 2.310; 95% confidence interval [CI]: 1.32–4.05), shorter duration of BZ use (<1 year) (odds ratios: 1.512; 95% CI: 1.02–2.25), no adverse events (odds ratios: 10.369; 95% CI: 6.13–17.54), larger reduction of diazepam-equivalent dose of BZs upon introducing lemborexant prescription (odds ratios: 1.150; 95% CI: 1.04–1.27), and suvorexant was the replacement drug (odds ratios: 2.983; 95% CI: 1.44–6.19), which were significant predictors of good response.

Conclusion

Although this is a retrospective and observational study with many limitations, our study results suggest that lemborexant is effective and safe.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sleep Medicine: X
Sleep Medicine: X Medicine-Medicine (all)
CiteScore
4.00
自引率
0.00%
发文量
17
审稿时长
25 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信